Old Mission Capital LLC Morpho Sys Ag Transaction History

Old Mission Capital LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.72 - $8.6 $164,129 - $210,046	24,424 New	24,424 $164,000
Q2 2022 Aug 05, 2022	BUY	$4.51 - $7.39 $182,488 - $299,021	40,463 New	40,463 $195,000
Q3 2021 Nov 12, 2021	SELL	$11.76 - $19.51 $429,886 - $713,188	-36,555 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$18.95 - $23.95 $692,717 - $875,492	36,555 New	36,555 $704,000
Q1 2021 May 14, 2021	SELL	$21.56 - $30.66 $746,967 - $1.06 Million	-34,646 Closed	0 $0

Q3 2020 Nov 16, 2020	SELL	$30.28 - $35.72 $498,863 - $588,487	-16,475 Reduced 32.23%	34,646 $1.09 Million
Q2 2020 Aug 12, 2020	BUY	$24.08 - $33.35 $1.23 Million - $1.7 Million	51,121 New	51,121 $1.62 Million
Q2 2019 Aug 14, 2019	SELL	$23.24 - $26.76 $928,484 - $1.07 Million	-39,952 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$22.55 - $29.84 $452,059 - $598,202	20,047 Added 100.71%	39,952 $908,000
Q4 2018 Feb 14, 2019	BUY	$21.96 - $31.02 $191,447 - $270,432	8,718 Added 77.93%	19,905 $504,000
Q3 2018 Nov 14, 2018	BUY	$26.64 - $35.66 $298,021 - $398,928	11,187 New	11,187 $299,000

11.3M

320K

1.1M

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.54B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Old Mission Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Old Mission Capital LLC with notifications on news.